TRVN Key Statistics, Chart & Performance
The current stock price of TRVN is 2.5 USD. In the past month the price decreased by -50.98%. In the past year, price decreased by -82.14%.
TRVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About TRVN
Company Profile
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
Company Info
TREVENA INC
955 Chesterbrook Boulevard, Suite 110
Chesterbrook PENNSYLVANIA 19087 US
CEO: Carrie L. Bourdow
Employees: 23
Phone: 16103548840
TREVENA INC / TRVN FAQ
Can you describe the business of TREVENA INC?
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
What is the stock price of TREVENA INC today?
The current stock price of TRVN is 2.5 USD. The price decreased by -45.71% in the last trading session.
What is the dividend status of TREVENA INC?
TRVN does not pay a dividend.
What is the ChartMill rating of TREVENA INC stock?
TRVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists TRVN stock?
TRVN stock is listed on the Nasdaq exchange.
Can you provide the number of employees for TREVENA INC?
TREVENA INC (TRVN) currently has 23 employees.
What is TREVENA INC worth?
TREVENA INC (TRVN) has a market capitalization of 2.13M USD. This makes TRVN a Nano Cap stock.
TRVN Technical Analysis
TRVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TRVN. TRVN may be in some trouble as it scores bad on both profitability and health.
TRVN Financial Highlights
Over the last trailing twelve months TRVN reported a non-GAAP Earnings per Share(EPS) of -16.38. The EPS decreased by -265.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -264.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRVN Forecast & Estimates
8 analysts have analysed TRVN and the average price target is 102 USD. This implies a price increase of 3980% is expected in the next year compared to the current price of 2.5.
For the next year, analysts expect an EPS growth of -916.33% and a revenue growth -95.22% for TRVN